MEDFORD, MA

HEPREGEN

Grant: $499,800 - National Institutes of Health - Sep. 30, 2009

Are you satisfied with this award? or

No votes have been cast for this award yet

Join the conversation: Post a comment about this award


Award Description: TOWARDS A MINIATURIZED HUMAN LIVER ARRAY FOR HIGH-THROUGHPUT SCREENING Animal studies are proving to be insufficient for predicting human liver responses primarily due to significant species-specific differences in liver functions. Therefore, a plethora of in vitro human liver models have been developed over the last three decades to supplement testing on animals. Of the several liver models currently available, those utilizing primary hepatocytes strike a good balance between their potential to predict the diverse human responses seen in vivo and their simplicity of use in various culture formats. However, primary hepatocytes are notoriously difficult to maintain in conventional models as their phenotypic functions display a precipitous decline within a few hours after isolation from the native microenvironment of the liver. Indeed, unstable hepatocytes in these models have been shown to be poor predictors of clinical outcomes. We have utilized microfabrication technologies and tissue engineering techniques to develop a human liver model with precise microscale cytoarchitecture and optimal stromal interactions that displays phenotypic stability for several weeks in vitro as compared to a few hours in conventional cultures. Here, we propose to further develop and optimize these microscale human liver cultures and couple them with miniaturization strategies and assay technologies for cost-effective high-throughput screening (HTS) applications. Since drug-induced liver injury (DILI) is a leading cause of acute liver failures and the high attrition rate of pharmaceuticals, we will optimize our miniaturized human livers specifically for the in vitro screening of genotype-specific and clinically-relevant drug disposition and coupled DILI. The technologies we develop here may find broad utility in the development of several classes of therapeutic compounds (drugs, biologics), in evaluating the disposition and injury potential of environmental toxicants, in fundamental investigations of liver physiology and disease, and in personalized medicine for liver disease. In the future, continued combination of microtechnology with tissue engineering may spur the development of other tissue models and their integration into the so-called ?human-on-a-chip?.

Project Description: Project has not yet started

Jobs Summary: No jobs created yet. (Total jobs reported: 0)

Project Status: Not Started

This award's data was last updated on Sep. 30, 2009. Help expand these official descriptions using the wiki below.


Funds Recipient

HEPREGEN
WINCHESTER, MA 01890
See more awards to this recipient

Place of Performance

200 Boston Avenue
Suite 1500
Medford, MA 02155
See more awards in this zip code



Wiki Description

No comments have been added for this project.

Edit the Wiki Description (editing policy)


Post a comment